Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTHAR Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia

NCT01373372
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Acthrel
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

NCT02446886
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Not applicable Interventional

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

NCT01367964
View directory record Official record
Conditions
West Syndrome
Interventions
adrenocorticotropin hormone
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Months to 12 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

NCT01906658
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Repository corticotropin injection
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression

NCT00001479
View directory record Official record
Conditions
Fatigue Syndrome, Chronic, Healthy, Mood Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900
View directory record Official record
Conditions
Cushing Syndrome
Interventions
LCI699
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Cape Coral, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 4 Interventional

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

NCT01021540
View directory record Official record
Conditions
Nephrotic Syndromes
Interventions
Repository corticotrophin
Drug
Lead sponsor
Arizona Kidney Disease and Hypertension Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 22, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

NCT01018992
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
GSK561679, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study

NCT03709381
View directory record Official record
Conditions
Adrenal Insufficiency, Osteopenia, Osteoporosis, Steroid Suppression of ACTH Secretion
Interventions
Low Dose Cosyntropin (ACTH) stimulation test, High Dose Cosyntropin (ACTH) stimulation test
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)

NCT01764711
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Cosyntropin administration
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Adrenocorticotropic Hormone Gel
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Great Neck, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

NCT06344143
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Various labs and imaging tests
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 5:14 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

NCT04080076
View directory record Official record
Conditions
Renal Disease
Interventions
Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
65 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lawrenceville, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NCT02258217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Acthar
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

ACTH Gel Therapy in Rheumatoid Arthritis

NCT02030028
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ACTHAR gel
Drug
Lead sponsor
Dana Ascherman
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 5:14 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

NCT04546126
View directory record Official record
Conditions
Radiotracer, Hypertension, Cholesterol
Interventions
Dexamethasone (Group 2), Cosyntropin (Group 3), PET/CT Scan with FNP-59
Drug · Combination Product
Lead sponsor
Benjamin Viglianti
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 22, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Adrenal Contribution to Androgen Production in Girls During Puberty

NCT01062568
View directory record Official record
Conditions
Development
Interventions
Adrenocorticotropin, Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed Phase 4 Interventional

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

NCT05546047
View directory record Official record
Conditions
Fibrillary Glomerulonephritis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Lawrenceville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 22, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

NCT00005890
View directory record Official record
Conditions
Septic Shock
Interventions
corticotropin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Month to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 5:14 PM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 22, 2026, 5:14 PM EDT